- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 172 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 241 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 12.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events | 2 | GlobeNewswire (USA) | ||
| 27.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders | 1 | GlobeNewswire (USA) | ||
| 17.02. | Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans | 1 | Benzinga.com | ||
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 816 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 05.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Welcomes New Members of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 02.02. | Micro-cap Polaryx Therapeutics to trade on the Nasdaq today via direct listing | 2 | Renaissance Capital | ||
| 02.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" | 284 | GlobeNewswire (Europe) | PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 30.01. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq | 242 | GlobeNewswire (Europe) | PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 27.01. | Polaryx Therapeutics, Inc. - 8-A12B, Registration of securities | 2 | SEC Filings | ||
| 27.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 14.01. | Polaryx Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 21.11.25 | Rare disease biotech Polaryx Therapeutics files for a direct listing on the Nasdaq | 4 | Renaissance Capital |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,580 | -22,78 % | Summit Therapeutics Inc. - 10-Q, Quarterly Report | ||
| BIONTECH | 88,20 | +0,06 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| ERASCA | 10,120 | -4,89 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,36 | +2,76 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| EVOTEC | 5,240 | +4,70 % | Evotec kassiert Millionen-Förderung: KI und neue Therapien im Fokus - unterschätzter Kurstreiber? | Evotec SE meldet einen strategisch wichtigen Erfolg: Gleich zwei neue Förderzusagen der Gates Foundation stärken die Forschung im Bereich Tuberkulose. Insgesamt fließen rund 9,9 Millionen US-Dollar... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| COGENT BIOSCIENCES | 36,340 | +1,65 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,030 | -2,32 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| MINERALYS THERAPEUTICS | 28,960 | +8,71 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| RECURSION PHARMACEUTICALS | 3,435 | -0,87 % | Recursion Pharmaceuticals: Recursion Announces Board Transition | Salt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson... ► Artikel lesen | |
| BEAM THERAPEUTICS | 31,160 | +2,80 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| ARVINAS | 10,820 | +9,29 % | FDA-Zulassung für Brustkrebsmittel VEPPANU beflügelt Arvinas-Aktie | ||
| CG ONCOLOGY | 66,25 | -0,75 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 53,55 | -0,39 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,220 (-4,20 %) liegt der Kurs bei 5,020 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.